Can azithromycin (Z pack) be given with rivaroxaban (Xarelto)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Azithromycin (Z-Pack) Be Given with Rivaroxaban (Xarelto)?

Yes, azithromycin can be safely co-administered with rivaroxaban without dose adjustment, as azithromycin does not significantly inhibit the CYP3A4 or P-glycoprotein pathways that affect rivaroxaban metabolism.

Pharmacokinetic Rationale

The key to understanding this interaction lies in rivaroxaban's elimination pathways. Rivaroxaban is metabolized primarily through CYP3A4 and eliminated via P-glycoprotein transport 1. Only drugs that act as strong inhibitors of BOTH CYP3A4 AND P-glycoprotein simultaneously cause clinically significant increases in rivaroxaban levels 1.

Drugs That ARE Contraindicated with Rivaroxaban:

  • Azole antifungals (ketoconazole, itraconazole, voriconazole, posaconazole) - these increase rivaroxaban exposure by approximately 2.5-fold 1, 2
  • HIV protease inhibitors (ritonavir) - these increase rivaroxaban exposure by 153% 1, 2

Drugs That Require Caution (Moderate Single-Pathway Inhibitors):

  • Clarithromycin - increases rivaroxaban exposure by 54% (strong CYP3A4/moderate P-gp inhibitor) 1, 2
  • Erythromycin - increases rivaroxaban exposure by 34% (moderate CYP3A4/P-gp inhibitor) 1, 2

Azithromycin's Safety Profile:

Azithromycin is NOT a significant CYP3A4 inhibitor and does not substantially affect P-glycoprotein 3. Unlike clarithromycin and erythromycin, azithromycin is not hepatically metabolized through the cytochrome P450 system 3. This fundamental difference in metabolism explains why azithromycin does not produce the same drug interactions as other macrolides 3.

Clinical Decision Algorithm

Step 1: Verify baseline renal function before prescribing rivaroxaban with any antibiotic 1

  • If CrCl >50 mL/min: standard rivaroxaban dosing
  • If CrCl 30-50 mL/min: consider dose reduction of rivaroxaban 1
  • If CrCl 15-30 mL/min: reduce rivaroxaban dose 1
  • If CrCl <15 mL/min: do not prescribe rivaroxaban 1

Step 2: Assess liver function 1

  • Child-Pugh A: no adjustment needed 1
  • Child-Pugh B: consider rivaroxaban dose reduction 1
  • Child-Pugh C: do not prescribe rivaroxaban 1

Step 3: Review all concomitant medications for additive bleeding risk 1, 4

  • Avoid triple therapy (rivaroxaban + NSAID + antiplatelet) as this substantially increases bleeding risk 4, 5
  • If patient is on aspirin or NSAIDs, counsel about increased bleeding risk but azithromycin does not add to this concern 1

Step 4: Prescribe azithromycin at standard doses without rivaroxaban adjustment

Important Caveats

Monitor for Bleeding Signs:

Even though azithromycin doesn't interact pharmacokinetically with rivaroxaban, all patients on anticoagulation require bleeding surveillance 1, 4:

  • Unusual bruising
  • Prolonged bleeding from cuts
  • Black/tarry stools
  • Blood in urine
  • Hemoptysis

Common Pitfall to Avoid:

Do not confuse azithromycin with clarithromycin or erythromycin 1. While clarithromycin and erythromycin require caution with rivaroxaban due to moderate increases in drug exposure, azithromycin does not share this interaction profile 2, 3.

Special Populations Requiring Extra Vigilance:

  • Elderly patients: increased baseline bleeding risk regardless of drug interactions 1
  • Moderate renal impairment (CrCl 15-49 mL/min): altered rivaroxaban pharmacokinetics independent of azithromycin 1
  • Patients on multiple medications: ensure no other strong CYP3A4/P-gp inhibitors are present 1, 2

Drugs That Decrease Rivaroxaban Efficacy

Be aware that strong CYP3A4 inducers reduce rivaroxaban levels and should be avoided 1:

  • Rifampin (50% decrease in rivaroxaban exposure) 1, 6
  • Phenytoin 1
  • Carbamazepine 1
  • Phenobarbital 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Concomitant Use of Anticoagulants and NSAIDs

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Atrial Fibrillation with Rivaroxaban, Metoprolol, and Flecainide

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.